Background--The transient receptor potential vanilloid type 1 (TRPV1) is expressed in the cardiovascular system, and increased TRPV1 expression has been associated with cardiac hypertrophy. Nevertheless, the role of TRPV1 in the pathogenesis of cardiac hypertrophy and the underlying molecular mechanisms remain unclear.
T ransient receptor potential vanilloid type 1 (TRPV1) is a 6-transmembrane tetrameric nonselective cation channel found mainly in the nociceptive neurons of the peripheral nervous system. Activation of TRPV1 leads to a painful sensation. 1, 2 TRPV1 is activated by a wide variety of physical and chemical stimuli. Exogenous activators of TRPV1 include capsaicin (CAP) and temperatures >43°C, whereas endogenous activators include endocannabinoids anandamide (ANA) and N-arachidonoyl dopamine. [3] [4] [5] In addition to the peripheral sensory neurons, TRPV1 is found in the cardiovascular system in, for example, cardiomyocytes, cardiac blood vessels, and coronary endothelial cells. 6, 7 Studies have implicated the role of endogenous activator ANA in multiple cardiovascular diseases, such as myocardial ischemia reperfusion injury and hypertension. 8, 9 Recently, increased TRPV1 expression was associated with cardiac hypertrophy in mice, and functional knockout of TRPV1 protected heart function in a model of cardiac hypertrophy. 6, 10 Furthermore, administration of a TRPV1 antagonist can overcome loss of heart function.
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Although these studies imply that TRPV1 antagonism may represent an exploitable therapy for cardiac hypertrophy and heart failure, much less is known about the underlying molecular events associated with cardiac hypertrophy. Considering the function of TRPV1 as a Ca 2+ -permeable channel and the pivotal role that Ca 2+ plays in regulation of long-term structural remodeling or degenerative processes in the heart, 12 we reasoned that increased TRPV1 expression would contribute to the elevated influx of Ca 2+ and downstream signaling pathways that play a role in cardiac hypertrophy. The aim of this study was to explore intracellular TRPV1 signaling in cultured cardiomyocytes cells in vitro and in cardiac hypertrophy induced by transverse aorta constriction (TAC) in vivo. The findings from this study provide justification for further studies into the role of TRPV1 in cardiac hypertrophy and raise the possibility that TRPV1 antagonists currently used as antihyperalgesics could be repurposed as agents against cardiac hypertrophy.
Materials and Methods

Culture of Neonatal and Embryonic Rat Cardiomyocytes
All animal experiments and procedures were approved by the institutional animal care and use committee at the Fourth Military Medical University. In vitro culture of neonatal rat cardiomyocytes was performed as described previously. 13 Briefly, Wister rats aged 2 to 3 days were anesthetized and decapitated. The hearts were minced and dissociated with 0.25% trypsinase (Sigma-Aldrich) in an incubator with 5% CO 2 at 37°C for 15 minutes. Dispersed cells were seeded at 2910 5 cells/cm 2 with DMEM supplemented with 10% fetal bovine serum (Gibco) in culture dishes and cultured in a 5% CO 2 incubator at 37°C. The H9C2 cell is a subclone of the original clonal cell line derived from embryonic rat heart tissue, which was purchased from American Type Culture Collection (ATCC, Rockville, MD) and cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin at 37°C in a humidified incubator containing 95% air and 5% CO 2 .
Transverse Aorta Constriction Procedures and TRPV1 Antagonist Capsazepine Treatment In Vivo
The TAC or sham surgery described previously was performed. 14 Briefly, C57BL/6 male mice (aged 7 weeks; Fourth
Military Medical University Medical Laboratory Animal Center, Xi'an, People's Republic of China) were anesthetized with a mixture of ketamine and xylazine. The transverse aorta between the brachiocephalic and left carotid arteries was banded using 6-0 silk ligature around the vessel and a 26-gauge needle, after which the needle was withdrawn. Sham surgeries were identical apart from the constriction of the aorta. All animal experiments and care procedures were reviewed and approved by the Animal Resource Center of the Fourth Military Medical University, and the methods were carried out in strict accordance with the approved guidelines. To study the role of TRPV1 blocking in TAC-induced cardiac hypertrophy mice, the TRPV1 antagonist capsazepine (CPZ; 0.25 and 1.25 mg/kg) was given to the mice intraperitoneally twice daily starting 24 hours after TAC operation through 4 or 8 weeks. Control mice were treated using 10% DMSO in saline, and the final volume was 120 lL.
Downregulation of Trpv1 Gene Expression by Small Interfering RNA
To silence the Trpv1 gene in cardiomyocytes, we performed transfection with small interfering RNA (siRNA) duplex, as described by the manufacturer (Santa Cruz Biotechnology). A pool of 3 different Trpv1 siRNAs was synthesized by Sangon Biotech (Shanghai, People's Republic of China): siRNA 1, sense GAAGACCUGUCUGCUGAAAtt, antisense UUUCAGCAGACAGGUCUUCtt; siRNA 2, sense CGAGCAUGUACAAUGAGAUtt, antisense AUCUCAUUGUACAUGCUCGtt; siRNA 3, sense CGCAUCUUCUACUUCAACUtt, antisense AGUUGAAGUAGAAGAUGCGtt. A nonrelated scrambled siRNA was used as a control. All measurements were performed 72 hours after transfection, at which time TRPV1 levels were decreased by 60% to 65%.
Real-Time Polymerase Chain Reaction for TRPV1, Ornithine Decarboxylase, and Atrial Natriuretic Peptide
Total RNA was extracted using TRIzol (Life Technologies Corporation). Using the RT-PCR Access Kit (Life Technologies Corporation), 1 µg total RNA was reverse transcribed into cDNA; 1 lL cDNA was used for polymerase chain reaction. TRPV1, ornithine decarboxylase (ODC), atrial natriuretic peptide, and b-actin mRNAs were amplified by polymerase chain reaction using the primers shown in Table 1 . The polymerase chain reaction mixture was incubated in a DNA Thermal Cycler (Stratagene). Reactions were prepared in triplicate and heated to 95°C for 5 minutes, followed by 40 cycles at 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 30 seconds. The resulting relative increase in reporter fluorescent dye (SYBR green) emission was monitored with the use of the ABI PRISM7700 sequence detector (Applied Biosystems). Relative quantification was measured using the comparative threshold method (DDCT), as described previously. 15 
Echocardiography Measurement of Left Ventricular Hypertrophy and Systolic Function
Echocardiography was performed using an Accuson Sequoia instrument paired with a 14-MHz transducer to study left ventricular (LV) hypertrophy and systolic function. After light anesthesia (100 mg/kg ketamine and 10 mg/kg xylazine), the animal was shaved, placed in a supine position, and warmed using an isothermal heating pad. LV internal end-diastole and -systole dimensions were measured from M-mode tracings as well as from interventricular septum and posterior wall thickness. LV fractional shortening was calculated using the following equation: (LV internal end-diastole dimensionÀLV internal end-systole dimension/LV internal end-diastole dimension)9100. Ejection fraction was calculated as follows: (LV end-diastole volumeÀLV end-systole volume/LV end-diastole volume)9100.
High-Performance Liquid Chromatography Analysis of Polyamines
According to our previously reported method, 16 the samples were homogenized in 700 lL of 0.9% sodium chloride mixed with 10 lL (200 nmol/mL) internal standard (1, 7-diaminoheptane). To precipitate proteins, 300 lL of trichloroacetic acid (0.5 mol/L) was added to the homogenate. After 30 minutes of incubation in ice, the homogenate was centrifuged for 30 minutes at 14 500g at 4°C. The derivatization reaction was carried out with 9-fluorenylmethyl chloroformate, and the fluorescent-polyamine derivatives were performed using C18 high-performance liquid chromatography columns (15094.6 mm, 5 lm) with a fluorescence detector (Jasco 821-FP) filled with 3 g reverse-phase material from Chrompack Nederland (chloroquine phosphate microspheres). The excitation and emission wavelengths of the detector were set at 264 and 310 nm, respectively. The solvent flow was 2 mL/min (acetonitrile:acetate 60/40 vol/ vol) and was followed by a linear increase of acetonitrile concentration to 95% in 30 minutes. The samples were dissolved in 50 mmol/L sodium acetonitrile:acetate 50/50 (vol/vol). The injection volume was 20 lL. 
Statistical Analyses
Values are shown as meanAESEM. Comparisons between the groups were conducted with ANOVA and Student t tests for unpaired and paired samples (t test). A post hoc comparison for ANOVA was done with the Fisher protected least squares difference test, and differences were considered significant at P<0.05.
Results
TRPV1 Activation Induced Cardiac Hypertrophy In Vitro
To examine the role of TRPV1 in cardiac hypertrophy, we treated isolated rat neonatal cardiomyocytes and the H9C2 cells with CAP and ANA, respectively. We found that 0.5 or 2 lmol/L CAP significantly increased the cell size in H9C2 cells, and 2 lmol/L CPZ reversed the increased cell size; however, only 2 lmol/L ANA induced a significant increase in size of H9C2 cells, whereas 2 lmol/L CPZ reversed this effect ( Figure 1A ). In cultured rat neonatal cardiomyocytes, cell size was increased by 2 lmol/L CAP or ANA, and that effect was ameliorated by 2 lmol/L CPZ treatment ( Figure 1B ). Next, atrial natriuretic peptide transcript expression, a marker of the hypertrophic response, was analyzed in H9C2 cells after CAP or ANA treatment, and atrial natriuretic peptide expression was increased significantly by CAP or ANA; 2 lmol/L CPZ treatment attenuated the increased atrial natriuretic peptide expression level induced by TRPV1 agonist CAP or ANA ( Figure 1C ). found predominantly in the heart has been shown to play an essential role in cardiac hypertrophy. 17 We explored whether
CaMKII d activity and phosphorylation were altered in TRPV1 activation-induced cardiac hypertrophy. Western blot analysis showed that CAP treatment (0.5 or 2 lmol/L) for 24 or 48 hours induced an increase in expression of phosphorylated CaMKII d in cardiac myocytes (Figure 2A and 2B) that was attenuated by CPZ treatment. Next, we observed the possible change in mitogenactivated protein kinases (MAPKs) including ERKs, JNK, and p38 in CAP-treated cardiac myocytes. The expression of phosphorylated ERKs, p38, and JNK proteins was assessed in H9C2 cells cultured with CAP for 24 or 48 hours. We observed increased expression of phosphorylated ERKs and p38 but not JNK in CAP-cultured H9C2 cells ( Figure 2C-2E) , and those increases were largely attenuated by CPZ treatment.
Downregulation of CaMKII d -Dependent MAPKs in Trpv1-Silencing Cardiomyocytes
To confirm whether phosphorylated CaMKII d was induced by TRPV1 activation and whether ERKs or p38 is downstream of phosphorylated CaMKII d , we knocked down expression of TRPV1 in H9C2 cells using Trpv1 siRNA and KN-93, the selective inhibitor of CaMKII d . Compared with the scrambled siRNA-treated cardiac myocytes, CAP (0.5 and 2 lmol/L) was not able to induce an increase in expression of phosphorylated CaMKII d , ERKs, and p38 in TRPV1 siRNA-treated cells. Moreover, in the presence of 2 lmol/L KN-93, CAP-induced expression of phosphorylated ERKs or p38 protein was significantly attenuated (Figure 3) . We evaluated whether MAPKs were able to induce expression of ODC, the first and rate-limiting enzyme in polyamine biosynthesis. 18, 19 We found that CAP (2 lmol/L) was able to induce a significant increase in protein expression of ODC; however, in the presence of KN-93 or the p38-selective inhibitor BIRB-796, the expression of ODC was greatly downregulated. Interestingly, in the Trpv1 siRNAtreated cardiomyocytes, CAP was not able to induce a significant increase in ODC protein expression (Figure 4 ). This indicated that TRPV1 activation-induced ODC expression was dependent on the CaMKII d -MAPK pathway.
TRPV1 Antagonist Treatment Produced Beneficial Effects in TAC-Induced Cardiac Hypertrophy
Because the presented data showed that the TRPV1 antagonist CPZ alleviated CAP-or ANA-induced cardiac hypertrophy in vitro, we next evaluated the effect of CPZ in TAC-induced cardiac hypertrophy in vivo. Histological analysis showed that CPZ-or vehicle-treated mice that underwent sham surgery showed no significant difference in cell size, whereas vehicletreated mice that underwent TAC had a significantly larger cross-sectional area of cardiomyocytes compared with CPZtreated mice (0.5 and 2.5 mg/kg) that underwent TAC ( Figure 5A and 5B). In addition, heart weight/body weight ratios in mice treated with 0.5 and 2.5 mg/kg CPZ and TAC were significantly lower compared with vehicle-treated mice that underwent TAC ( Figure 5C ). Next we measured the effect of CPZ on cardiac function in sham-or TAC-treated mice. There was no significant difference between the sham-and TAC-treated mice in heart rate, but measurements of LV internal end-diastole andsystole diameters revealed that vehicle-treated mice had significantly more dilated ventricles at 4 and 8 weeks after TAC than mice treated with 0.5 and 2.5 mg/kg CPZ. Most notably, the ejection fraction percentage was significantly better at 36 days after TAC in mice treated with 0.5 and 2.5 mg/kg CPZ than in vehicle-treated mice. This fractional shortening percentage indicates significantly better heart function ( Figure 5D , Table 2 ). There is a linear trend between the CPZ concentration and progress in cardiac function.
Increased Expression of TRPV1 in Pressure Overload-Induced Cardiac Hypertrophy In Vivo
It has been reported that TRPV1, TRPV4, and TRPM6 were the TRP family members expressed primarily in the cardiovascular system; therefore, we tested whether expression of these TRP family members was altered during cardiac hypertrophy and CPZ treatment in vivo. The results showed that TAC induced a significant increase in expression of TRPV1 protein (Figure 6A) but not TRPV4 or TRPM6 (Figure 6B and 6C) . After CPZ treatment of 2.5 mg/kg per day for 8 weeks, expression of TRPV1 protein was decreased, and there was no obvious change in TRPV4 or TRPM6 protein expression after CPZ treatment ( Figure 6 ). These results revealed that TRPV1 played a pivotal role in the TRPV family for cardiac pathophysiology, and CPZ treatment attenuated the TACinduced expression of TRPV1.
TRPV1 Antagonist Treatment Decreased Expression of Cardiac ODC and Polyamine Level in TAC-Treated Mice
Because our results showed that TRPV1 activation induced an increase in ODC expression through CaMKII and the MAPK signaling pathway in vitro, we further evaluated the effects of TAC treatment on the expression of ODC and polyamine level and whether CPZ was able to reverse the effect in vivo. Real-time polymerase chain reaction and Western blot analysis showed that ODC expression increased significantly for 4 or 8 weeks after TAC treatment compared with sham surgery, whereas 2.5 mg/kg per day CPZ treatment reversed the increase in ODC expression ( Figure 7A-7D) . High-performance liquid chromatography data showed that TAC-treated mice had higher concentrations of cardiac polyamines, including putrescine, spermidine, and spermine, and CPZ caused a reduction in cardiac polyamine level following TAC treatment ( Figure 7E and 7F). Because polyamines contribute to several physiological and pathological processes, including cardiac hypertrophy, 14 modifications in polyamine homeostasis by CPZ treatment might benefit cardiac function.
CPZ Reverses TAC-Induced Cardiac Hypertrophy Through CaMKII d and the MAPK Signaling Pathway In Vivo
Our results showed that activation of TRPV1 induced an increase in intracellular calcium and phosphorylated CaMKII ddependent MAPK signaling and that expression of TRPV1 was upregulated in TAC-induced hypertrophic hearts in vivo; therefore, we assayed the expression of CaMKII d and MAPK proteins in TAC-induced cardiac hypertrophy in vivo. Western blot analysis showed that TAC treatment for 4 or 8 weeks also induced an increase in phosphorylated CaMKII d in cardiac myocytes ( Figure 8A and 8B) that was attenuated by CPZ treatment of 2.5 mg/kg per day in vivo. To observe the change of MAPK signaling components after CPZ treatment in TAC-induced cardiac hypertrophy in vivo, we further measured the expression of phosphorylated ERKs, p38, and JNK proteins in the sham-and TAC-operated mice and analyzed the effect of CPZ on expression of these MAPKs. The results showed increased expression of phosphorylated ERKs and p38 but not phosphorylated JNK in TAC vehicle groups, and this effect was reversed by CPZ treatment of 2.5 mg/kg per day ( Figure 8A , 8C-8E).
Sarcoplasmic reticulum Ca 2+ handling plays an important role in chronic cardiac hypertrophy and remodeling, and the coupling of workload is partly dependent on mitochondrial Ca 2+ uniporter activity. 15 To address this issue, we observed the expression of cardiac muscle Serca2a, which is the key regulator of cardiac diastolic function, and PLN, a 52-amino acid integral membrane protein that regulates the function of Serca2a. The results showed that expression of phosphorylated PLN was significantly decreased in the hearts of TACtreated mice for 8 weeks, and this decrease was reversed by CPZ treatment; however, there was no significant difference in expression of Serca2a between sham and TAC groups ( Figure 8F and 8G).
Discussion
TRPV1 receptors act as transducers and molecular integrators of nociceptive stimuli in the periphery. 20, 21 They are also found in multiple target tissues and cell types in the heart, and a number of research articles show that TRPV1 regulation can affect cardiopathologies. 6, 22, 23 Previous results showed that mice lacking functional TRPV1 or mice treated with TRPV1 antagonist had improved heart function and reduced hypertrophic, fibrotic, and apoptotic markers using TAC to model pressure overload cardiac hypertrophy. 10, 24 The present study reveals that increased expression of TRPV1 in TAC-treated mice and activation of TRPV1 is able to induce cardiohypertrophic response in vitro. Although TRPV1 was initially identified as the receptor for CAP-the pungent ingredient in hot chili peppers-it has other functions, and multiple signals and inputs, such as pH, endogenous anandamide, protein kinase C phosphorylation, mechanosensitivity, and baroreflex, that activate TRPV1 are also associated with cardiohypertrophic conditions. [25] [26] [27] [28] [29] This indicates that TRPV1
plays an important role in cardiac physiology and in the progression of cardiac hypertrophy. Cardiac hypertrophy is characterized by a dysregulation in intracellular Ca 2+ homeostasis within cardiomyocytes, and it has been confirmed that this Ca 2+ influx is induced by a persistent increase of intracellular calcium concentration through L-type Ca 2+ channels and the activation of b-adrenergic receptors in failing hearts. 30, 31 Whether Ca 2+ influx through TRPV1 plays a role in this process remains unclear. In this study, Ca 2+ influx in cardiomyocytes subjected to TRPV1 activation was significantly increased. To investigate the mechanisms underlying TRPV1-induced Ca 2+ influx in the development of cardiac hypertrophy, we modulated calciumdependent kinase activity by compound KN-93 for inhibition of CaMKII, which is widely used for this purpose. 32 CAP-induced increase in cardiac hypertrophy was reduced by KN-93, and this implies that Ca 2+ CaMKII is involved in TRPV1 activation-induced cardiac hypertrophy. MAPKs are well characterized and have been reported to be important for the induction of hypertrophic responses and signaling in pressure overload-induced cardiac hypertrophy and remodeling. 33, 34 Although the link between TRPV1-mediated increases in intracellular calcium level and MAPK signaling is not fully understood, CAP-induced phosphorylation of ERKs and p38 was found in load-induced skeletal muscle hypertrophy, 35 whereas p38 was also required for TRPV1-mediated CAP-induced apoptosis of glioma cells. 36 The present study confirmed that CAP could induce phosphorylation of ERKs and p38 but not JNK in cardiomyocytes. Inhibition of CaMKII decreased the phosphorylation of ERKs and p38 induced by CAP. Our data continued to highlight the importance of TRPV1-mediated calcium signaling in intracellular signaling pathways, especially in the heart. The present results also demonstrated that TRPV1 activation markedly increased the concentrations of polyamines in the heart, including putrescine, spermidine, and spermine, and expression of ODC mRNA and protein. Because ODC and polyamines are required for cell growth, 37 the common belief is that the induction of cardiac ODC could be an obligatory step in heart hypertrophy induced by catecholamines. 38 Nevertheless, experiments using transgenic mice overexpressing ODC in the heart demonstrated that the robust expression of ODC is not sufficient by itself to promote heart hypertrophy but indicated that ODC may cooperate with other factors inducing cardiac growth. 39 Cardiac ODC induction by b-adrenoreceptor agonist was associated with the phosphorylation of ERKs, and the blockade of ODC induction by L-type calcium channel antagonists also prevented the phosphorylation of ERKs. This finding strongly suggests that the activation of the MAPK cascade appears to be important for the induction of cardiac ODC by catecholamines but requires critical concentration of free intracellular calcium. 40 Our results showed that TRPV1 activation-induced cardiac ODC was dependent on phosphorylation of p38 because the p38-selective inhibitor BIRB-796 could downregulate the expression of cardiac ODC induced by CAP. Moreover, CAP also induced an increase in intracellular calcium level, possibly requiring the activation of the p38 signaling pathway and ODC induction at the same time. Interestingly, our results also revealed that phosphorylation of PLN was decreased in TAC-induced cardiac hypertrophy. It has been reported that PLN inhibits Serca2a activity by decreasing the apparent affinity of the Serca2a for Ca 2+ , and this inhibition is relieved by phosphorylation of PLN at serine 16 or threonine 17. 41 This suggests that the activity of Serca2a in TAC-induced cardiac hypertrophy is inhibited because of decreased phosphorylation of PLN, resulting in a decrease in the rate of relaxation of cardiac muscle and a positive inotropic effect. In skeletal muscle sarcoplasmic reticulum, it was found that the Serca2a activity was inhibited by a variety of polyamines including spermine and spermidine, 42 so the activity of Serca2a in TAC-induced cardiac hypertrophy is inhibited either indirectly by a decrease in PLN phosphorylation or directly by elevated intracellular polyamine levels. Because the potential nonspecific nature of using TRPV1 agonists or antagonists in vitro may be magnified in the in vivo experiments, in which their effects likely affect all tissue types including nervous system and result in off-target effects, it will be interesting to observe the possible structural and functional change in heart-specific TRPV1 knockout mice after TAC treatment. The TRPV1 receptor is of great interest in the pharmaceutical industry as the molecular target for CAP, and CAP has been used as a treatment for pain because of its ability to desensitize TRPV1 channels in neurons. 43 As the first reported antagonist of TRPV1, CPZ has also been used in pharmacological studies. 44 Although early TRPV1 antagonists in the clinic showed worrisome adverse effects including hyperthermia and impaired noxious heat sensation, it is reported that at least 7 orally active TRPV1 antagonist substances have progressed into clinical development, and several more are in preclinical development. The ligand GRC 6211 (Eli Lilly and Company-Glenmark) is the most advanced and is currently in phase IIb clinical trials. 45 Taken together, upregulation of TRPV1 involved in cardiac hypertrophy was shown in the present study. Activation of TRPV1 induced increases in intracellular calcium levels and CAMKII/MAPK signaling. Increased cardiac ODC and intracellular polyamine levels as a consequence of phosphorylation of p38 also contributed to the pathogenesis of cardiac hypertrophy. In line with our results, Buckley et al 10 demonstrated that mice lacking functional TRPV1 or mice treated with TRPV1 antagonist have improved heart function and reduced hypertrophic, fibrotic, and apoptotic markers in a model of pressure overload. This suggests that TRPV1 plays a role in the progression of cardiac hypertrophy through intracellular calcium and CaMKII/MAPK-dependent polyamine pathways. Conclusively, TRPV1 antagonism provides an exploitable therapeutic advantage for the treatment of cardiac hypertrophy. 
